On June 4, 2025, the Phase I clinical study (ESG406-101) of the ADC drug ESG406, independently developed by Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen"), successfully administered the first dose to a participant. ESG406 received approval from the National Medical Products Administration on April 21, 2025, to conduct clinical research. The initiation of the ESG406-101 project marks the comprehensive iteration and upgrade of Escugen 's ADC technology. Moving forward, the company will focus on the pipeline development of the new generation of ADC technologies.

On June 2, 2025, Escugen's ESG401 (Trop2 ADC) was first reported at the 2025 ASCO meeting in the form of a poster, presenting the clinical trial data of ESG401 in salivary gland cancer.